Paxlovid: The study is a real-world study. According to the actual medical history of patients, the usage of paxlovid will be collected.
Study summary
The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.
Eligibility
Sex
ALL
Min age
12 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Participants who have a positive SARS-CoV-2 test result;
* Participants who have one or more mild or moderate COVID-19 symptoms.
Exclusion Criteria:
* No specific exclusion criteria in this real world study.
Primary outcome measure(s)
Viral shedding time — up to 28 days time from the first positive testing to the first day of nucleic acid Ct value\> 35 for both ORF1ab and N gene (in two consecutive).
Percentage of the participants who have progression of COVID-19 — up to 28 days Percentage of participants who experience these events by Day 28 Progress to severe and/or critical COVID-19; Death from any cause
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.